Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment

Data are limited regarding the real‐world effectiveness and safety of glecaprevir/pibrentasvir (GLE/PIB) in patients with chronic hepatitis C virus (HCV) infection and severe renal impairment (RI). We aimed to evaluate the performance of GLE/PIB in patients with chronic kidney disease (CKD) stage 4...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of viral hepatitis 2020-06, Vol.27 (6), p.568-575
Hauptverfasser:	Liu, Chen‐Hua, Yang, Sheng‐Shun, Peng, Cheng‐Yuan, Lin, Woan‐Tyy, Liu, Chun‐Jen, Su, Tung‐Hung, Tseng, Tai‐Chung, Chen, Pei‐Jer, Chen, Ding‐Shinn, Kao, Jia‐Horng
Format:	Artikel
Sprache:	eng
Schlagworte:	Alanine Alanine transaminase Bilirubin Chronic infection chronic kidney disease direct‐acting antiviral agent glecaprevir Heart surgery Hepatitis Hepatitis B Hepatitis C hepatitis C virus Interferon Kidney diseases Nausea Patients pibrentasvir Pruritus
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!